Cargando…

Comparison of the amount of SARS-CoV-2 exhaled by Delta and Omicron patients

Detalles Bibliográficos
Autores principales:	Lina, Liu, Zhendong, Guo, Sevalie, Stephen, Fangfang, Zhang, Dawei, Zhang, Weiwei, Chen, Xiao, Li, Zongzheng, Zhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd on behalf of The British Infection Association. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420242/ https://www.ncbi.nlm.nih.gov/pubmed/36044946 http://dx.doi.org/10.1016/j.jinf.2022.08.028

Ejemplares similares

Characteristics of SARS-CoV-2 exhaled by COVID-19 patients
por: Lina, Liu, et al.
Publicado: (2023)

High amounts of SARS-CoV-2 in aerosols exhaled by patients with Omicron variant infection
por: Zheng, Jing, et al.
Publicado: (2022)

SARS-CoV-2 Aerosol Exhaled by Experimentally Infected Cynomolgus Monkeys
por: Zhang, Chunmao, et al.
Publicado: (2021)

Will New Variants Emerge after Delta and Omicron?
por: Yang, Zhen, et al.
Publicado: (2022)

Cohorting inpatients with Omicron and Delta variants of Sars-CoV-2 does not increase rates of mixed infection
por: Davies, Jessica, et al.
Publicado: (2022)

The efficacy and safety of IBI314 on delta and omicron variant of SARS-CoV-2: First-in-human evidence
por: Sang, Ling, et al.
Publicado: (2022)

ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants
por: Ou, Jianxia, et al.
Publicado: (2022)

Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates
por: Bojkova, Denisa, et al.
Publicado: (2022)

Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo
por: Li, Mengjiao, et al.
Publicado: (2022)

Limit of Detection for Rapid Antigen Testing of the SARS-CoV-2 Omicron and Delta Variants of Concern Using Live-Virus Culture
por: Stanley, Sydney, et al.
Publicado: (2022)

Comparison of SARS-CoV-2 aerosol emission from patients with Omicron BA.1 or BA.2 subvariant infection
por: Zhang, Yidun, et al.
Publicado: (2022)

The SARS-CoV-2 Omicron Variant Does Not Have Higher Nasal Viral Loads Compared to the Delta Variant in Symptomatic and Asymptomatic Individuals
por: Laitman, Andrew M., et al.
Publicado: (2022)

Serial interval in households infected with SARS-CoV-2 variant B.1.1.529 (Omicron) is even shorter compared to Delta
por: an der Heiden, Matthias, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron and Delta Variants in Relation to Vaccine-Induced Antibody Levels in Kidney Transplant Recipients and Healthy Controls
por: Pedersen, Rune M., et al.
Publicado: (2022)

A case of breakthrough infection with SARS-CoV-2 Delta derivative and reinfection with Omicron variant in a fully vaccinated health care professional
por: Pandit, Priyanka, et al.
Publicado: (2022)

Identification of Omicron-Delta Coinfections Using PCR-Based Genotyping
por: Roychoudhury, Pavitra, et al.
Publicado: (2022)

Comparative analysis of transmission and vaccine effectiveness in Omicron and Delta variant outbreaks in China
por: Li, Kangguo, et al.
Publicado: (2023)

SARS-CoV-2 Omicron Replacement of Delta as Predominant Variant, Puerto Rico
por: Santiago, Gilberto A., et al.
Publicado: (2023)

Inferior cellular and humoral immunity against Omicron and Delta variants of concern compared with SARS-CoV-2 wild type in hemodialysis patients immunized with 4 SARS-CoV-2 vaccine doses
por: Anft, Moritz, et al.
Publicado: (2022)

Omicron variant in the current SARS-CoV-2 pandemic
por: Nasiri, Kaveh, et al.
Publicado: (2022)

Determinants of reinfection with SARS-CoV-2 Omicron variant
por: Bisharat, N., et al.
Publicado: (2023)

SARS-CoV-2 Delta and delta derivatives impact on neutralization of Covishield recipient sera
por: Sahay, Rima R., et al.
Publicado: (2022)

Impact of SARS-CoV-2 omicron BA.1 and delta AY.4.2 variants on the neutralization by sera of patients treated with different authorized monoclonal antibodies
por: Dragoni, Filippo, et al.
Publicado: (2022)

Antibody titers and breakthrough infections with Omicron SARS-CoV-2
por: Dimeglio, Chloé, et al.
Publicado: (2022)

High rate of reinfection with the SARS-CoV-2 Omicron variant
por: Nguyen, Nhu Ngoc, et al.
Publicado: (2022)

What Is New With Omicron Variant of SARS-CoV-2 in Children?
por: Bittmann, Stefan, et al.
Publicado: (2022)

SARS‐CoV‐2 omicron variant: Could it be another threat?
por: Shanmugaraj, Balamurugan, et al.
Publicado: (2022)

Comparison of the clinical and virological characteristics of SARS-CoV-2 Omicron BA.1/BA.2 and omicron BA.5 variants: A prospective cohort study
por: Kang, Sung-Woon, et al.
Publicado: (2023)

Neutralizing antibody responses in patients hospitalized with SARS-CoV-2 Delta or Omicron infection
por: Linderman, Susanne L., et al.
Publicado: (2022)

Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals
por: Faustini, Sian, et al.
Publicado: (2022)

Facepiece filtering respirators with exhalation valve should not be used in the community to limit SARS-CoV-2 diffusion
por: Ippolito, Mariachiara, et al.
Publicado: (2020)

Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction
por: Lan, Jun, et al.
Publicado: (2022)

Breakthrough infection shapes humoral immunity against SARS-CoV-2 Omicron Variant
por: Zhang, Yuwei, et al.
Publicado: (2023)

Highly efficient respirators are needed for the Omicron variant of SARS-CoV-2
por: Mattiuzzi, C., et al.
Publicado: (2022)

The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta
por: Liu, Ying, et al.
Publicado: (2022)

SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice
por: Baz, Mariana, et al.
Publicado: (2022)

Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant
por: Zhang, Na-Na, et al.
Publicado: (2022)

Vaccine‐breakthrough infection by the SARS‐CoV‐2 omicron variant elicits broadly cross‐reactive immune responses
por: Zhou, Runhong, et al.
Publicado: (2022)

Comparative neutralization profiles of naive and breakthrough infections with Delta, Omicron BA.1 and BA.2 variants of SARS-CoV-2
por: Yang, Yang, et al.
Publicado: (2022)

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
por: Li, Pengfei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0al57uree1ghbfiu326c61g6df